JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 65.9%

Neg 0% Neu 65.9% Pos 0%

JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.